The Malaysian Soy and Mammographic Density Study
NCT03686098 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 282
Last updated 2019-01-31
Summary
Globally, breast cancer is the most common cancer and the main cause of deaths due to cancer. This is attributed to changes in reproductive habits as well as an increasingly sedentary lifestyle, with low physical activity and diets rich in saturated fats but low in fiber. While the main focus in many Asian countries is to improve survival from breast cancer by encouraging early detection of the disease and improving access to cancer treatment, it does not reduce the number of women who will be diagnosed with breast cancer in the years to come. Currently, there is an urgent need to develop effective strategies to prevent breast cancer in Asia and beyond.
Soy may be an important dietary strategy for breast cancer prevention. Compared to women in the West, Asian women consume up to 10-fold more soy in their diet, which may, in part, explain their lower risk of breast cancer. Soybeans are rich in isoflavones, which can mimic estrogenic activity. In the body, it competes with estrogen and binds to estrogen receptor sites, thereby reducing the effect of estrogen and possibly lowering breast cancer risk.
Consistently, research has shown that Asian postmenopausal women who have high soy diets are less likely to be diagnosed with breast cancer. However, researchers have not been able to show that postmenopausal women can reduce their breast cancer risk by increasing soy intake as part of their diets. There are several reasons why these studies have failed to see an effect despite the body of evidence indicating that soy may be protective. Firstly, these are studies of Caucasian women who may have never been exposed to soy, particularly in adolescence, where soy may have the greatest impact. Also, these studies have used soy isoflavone supplements, rather than traditional soy foods made from whole soybeans, which may affect how soy is metabolized in the body. Lastly, the way in which mammographic density measurements were obtained previously could have negatively influenced the study results, such as the use of digitized images of mammogram films rather than raw digital images and the use of semi-automated methods that may be subject to human error and reader variability.
Therefore, a well-designed intervention study among Asian women living in Asia, using suitable mammographic density measures as a surrogate marker of breast cancer risk, will best answer these remaining gaps in our knowledge about the soy-breast cancer relationship.
Conditions
- Breast Cancer
- Mammographic Density
Interventions
- DIETARY_SUPPLEMENT
-
Dietary soy
Soy isoflavones delivered through diet, assisted by a detailed food guide for locally available soy-based foods.
- DIETARY_SUPPLEMENT
-
Soy Supplement
Soy isoflavones delivered in extracted form
Sponsors & Collaborators
-
University of Nottingham Malaysia
collaborator OTHER -
Subang Jaya Medical Centre
collaborator UNKNOWN - collaborator OTHER
-
Cancer Research Malaysia
lead OTHER
Principal Investigators
-
Soo Hwang Teo · Cancer Research Malaysia
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 45 Years
- Max Age
- 65 Years
- Sex
- FEMALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2018-11-19
- Primary Completion
- 2020-04-30
- Completion
- 2020-06-30
Countries
- Malaysia
Study Locations
More Related Trials
-
Exemestane in Reducing Breast Density in Postmenopausal Women at Risk for Breast Cancer
NCT00066586 ·Status: COMPLETED ·Phase: NA
-
Soy Protein Supplement In Treating Hot Flashes in Postmenopausal Women Receiving Tamoxifen for Breast Disease
NCT00031720 ·Status: COMPLETED ·Phase: PHASE2
-
Maximum Tolerated Dose, Safety and Pharmacologic Study of TRF in Women With Breast Cancer
NCT03855423 ·Status: UNKNOWN ·Phase: NA
-
Long-Term Effect of Adolescent Diet on Hormones and Breast Cancer Risk in Women Previously Enrolled in the Dietary Intervention Study in Children
NCT00458588 ·Status: COMPLETED
-
Iodine Supplementation on Breast Cancer
NCT03688958 ·Status: UNKNOWN ·Phase: PHASE2
-
Zoladex Plus Tamoxifen in Breast Cancer
NCT00827307 ·Status: COMPLETED ·Phase: NA
-
Breast Density, Hormone Levels, and Anticancer Drug Levels in Women With Invasive Breast Cancer Who Are Receiving Exemestane or Anastrozole
NCT00316836 ·Status: COMPLETED
-
Exemestane + Celecoxib vs Exemestane + Placebo in Metastatic Breast Cancer
NCT00525096 ·Status: COMPLETED ·Phase: PHASE3
-
Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer
NCT00573755 ·Status: TERMINATED ·Phase: PHASE2
-
Multicenter Follow Up Study Of Subjects Who Participated In An Original Protocol Of Exemestane Vs. Megestrol Acetate In Postmenopausal Women With Metastatic Breast Cancer
NCT01237327 ·Status: COMPLETED ·Phase: PHASE3
-
Quality of Life in Chinese Postmenopausal HR(+) Early Breast Cancer (EBC) Patients During Adjuvant Aromatase Inhibitors(AIs) Treatment
NCT01144572 ·Status: COMPLETED
-
Letrozole in Preventing Breast Cancer in Postmenopausal Women
NCT00090857 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of Adjuvant Endocrine Therapy With Aromatase Inhibitors on the Postoperative Lipid Levels in Postmenopausal Breast Cancer Patients
NCT02765373 ·Status: UNKNOWN
-
Quality of Life in Postmenopausal Women Who Are Receiving Either Exemestane or Anastrozole With or Without Celecoxib for Stage I, Stage II, or Stage IIIA Primary Breast Cancer
NCT00090974 ·Status: COMPLETED
-
Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer
NCT01151215 ·Status: TERMINATED ·Phase: PHASE2
-
A Nutritional Intervention to Decrease Breast Density Among Female BRCA (BReast CAncer Susceptibility Gene) Carriers
NCT02197000 ·Status: COMPLETED ·Phase: NA
-
Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
NCT06195306 ·Status: RECRUITING ·Phase: PHASE2
-
Changes in Breast Density and Blood Hormone Levels in Postmenopausal Women Receiving Anastrozole or Exemestane for Breast Cancer
NCT00516698 ·Status: COMPLETED
-
Goserelin/Letrozole in Premenopausal Patients vs Letrozole Alone in Postmenopausal Patients With MBC
NCT00532272 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Tamoxifen on Breast Density in Premenopausal Women With Breast Cancer or High Risk for Breast Cancer
NCT00086749 ·Status: COMPLETED
-
Black Cohosh in Treating Hot Flashes in Women Who Have or Who Are At Risk of Developing Breast Cancer
NCT00060320 ·Status: COMPLETED ·Phase: PHASE3
-
The Effects of EstroSense®/MD vs Placebo in Improving the Estrogen Profile in Females
NCT02385916 ·Status: COMPLETED ·Phase: NA
-
Effect of Oral (Z)-Endoxifen in Premenopausal Women With Measurable Breast Density
NCT05068388 ·Status: COMPLETED ·Phase: PHASE2
-
Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women
NCT00186121 ·Status: COMPLETED ·Phase: PHASE2
-
Steroid Aromatase Inhibitors Versus Progestogens for nSAID-resistanced Late Stage Breast Cancer
NCT02161315 ·Status: UNKNOWN